Filing Information

Inventor(s)	Man Sung Co ·
Assignee(s)	Protein Design Labs, Inc. ·  View assignee updates
Attorney/Agent(s)	Townsend & Townsend & Crew ·
Primary Examiner	Phillip Gambel ·
Application Number	US8579378
Filing date	12/27/1995
Issue date	04/03/2001
Predicted expiration date	12/01/2012
U.S. Classifications	424/154.1  · 435/343.2  · 424/141.1  · 424/143.1  · 424/144.1  · 424/153.1  · 424/173.1  · 435/326  · 435/328  · 435/332  · 435/343  · 435/343.1  · 424/133.1  · 530/387.1  · 530/387.3  · 530/388.1  · 530/388.2  · 530/388.22  · 530/388.7  · 530/388.73  · 530/388.75  · 536/231  · 536/235  · 536/235.3  · 424/130.1  ·
International Classifications	--
Kind Code	B1
International Classifications	4241301 · 4241321 · 4241331 · 4241411 · 4241431 · 4241441 · 4241531 · 4241541 · 4241731 · 435 696 · 4351723 · 4352523 · 4353201 · 435 7021 · 435452 · 435326 · 435328 · 435332 · 435334 · 435343 · 4353431 · 4353432 · 435346 · 536 234 · 536 235 · 536 2353 · 5303871 · 5303873 · 5303881 · 53038822 · 5303887 · 53038873 · 53038875 · 5303882 ·
Related U.S. Application Data	REFERENCE TO RELATED INVENTIONS This application is a continuation-in-part of U.S. Ser. No. 08/160,074, filed Nov. 30, 1993 now abandoned, which is a continuation-in-part of U.S. Ser. No. 07/983,946, filed Dec. 1, 1992 now abandoned. This application also derives priority from EP 95 112 895.8, filed Aug. 17, 1995, and EP 95 114 696.8, filed Sep. 19, 1995. All of the prior U.S. and foreign applications from which priority is derived are incorporated by reference in their entirety for all purposes.
Foreign Priority	EP95112895 - 08/17/1995 · EP95114696 - 09/19/1995 ·

Abstract

Independent Claims | See all claims (17)

1. 1. A humanized immunoglobulin having complementarity determining regions (CDRs) corresponding to CDRs from the mouse DREG-55 donor immunoglobulin and heavy and light chain variable region frameworks corresponding to human acceptor immunoglobulin heavy and light chain frameworks from the Gal antibody, provided that at least one position selected from the group consisting of L50, L62 and L74 is occupied by the amino acid present in the equivalent position of the mouse DREG-55 immunoglobulin light chain variable region framework, which humanized immunoglobulin specifically binds to human L-selectin with an affinity constant between 107 M−1 and five-fold the affinity of the mouse DREG-55 antibody, wherein the mouse DREG-55 antibody has light and heavy chain variable regions designated SEQ. ID. Nos. 14 and 16 respectively.
2. 10. A humanized immunoglobulin, wherein the amino acid sequence of the mature light chain variable region is shown in the lower lines of FIG. 2A (SEQ. ID. No. 6) and the amino acid sequence of the mature heavy chain variable region is shown in the lower lines of FIG. 2B (SEQ. ID. No. 8).
3. 11. A humanized immunoglobulin, wherein the amino acid sequence of the mature light chain variable region is shown in the lower lines of FIG. 7A (SEQ. ID. No. 18) and the amino acid sequence of the mature heavy chain variable region is shown in the lower lines of FIG. 7B SEQ. ID, No. 20).
4. 13. A humanized immunoglobulin having complementarity determining regions (CDRs) corresponding to CDRs from the mouse DREG-200 donor immunoglobulin and heavy and light chain variable region frameworks corresponding to a human acceptor immunoglobulin heavy and light chain frameworks from the Eu antibody, provided that at least one position selected from the group consisting of L87, L54, L66, L76 and at least one position selected from the group consisting of H93, H95, H98, H111, H112, H115, H30, H98, H111, H27, H30, H48 and H72, is occupied by the amino acid present in the equivalent position of the mouse DREG-200 immunoglobulin light or heavy chain variable region framework, which humanized immunoglobulin specifically binds to human L-selectin with an affinity constant between 107 M−1 and three-fold the affinity of the mouse DREG-200 antibody, wherein the mouse DREG-200 antibody has light and heavy chain variable regions designated SEQ. ID. Nos. 2 and 4 respectively.